Shield Therapeutics (LSE: STX)  has announced the appointment of Hans Peter Hasler as non-executive Chairman of the Company with effect from the Annual General Meeting which is to be held on 18 June 2020.  
 
As announced within the FY19 results on 21 May 2020, James Karis, the company's current Chairman, notified the Board of his intention to step down at the AGM on 18 June and not seek re-election. 
 
Hans Peter Hasler has therefore been appointed with effect from the AGM. Hans Peter joined Shield's Board of Directors in July 2018 and has served as Chairman of the Nomination Committee and a member of the Audit Committee.  
 

Hans Peter has had prior executive experience including as Chief Operating Officer at both Elan Corporation and Biogen Inc. as well as Chief Marketing Officer of Wyeth Pharmaceuticals, Radnor, PA.

Currently, he is non-executive Chairman of the Board of HBM Healthcare Investments AG, Zug / Switzerland and a non-executive director of Minerva Neuroscience Inc., Boston. Mr. Hasler holds a Federal Swiss Commercial Diploma and a Marketing Manager Certificate from the Swiss Institute of Business Economy SIB, Zurich, Switzerland. 
 
Shares in Shield have traded strongly off lows at the peek of the COVID-19 crisis of 54p to open flat today at 92p following this announcement.

 Hans Peter Hasler said, "I am delighted to have been appointed as Chairman of Shield at a critical time for the Group. Feraccru®/ Accrufer® is an excellent product with enormous potential and I look forward to continuing to help the Group find ways of making it available to the widest possible number of patients and to translating that into value for shareholders. I also look forward to working with the rest of the Board and the management team in these endeavours." 
 
Tim Watts, CEO of Shield Therapeutics, said: "I am very pleased to see Hans Peter appointed as our Chairman. I have worked increasingly closely with Hans Peter over the last two years and value his experience and insights and the support he has given me personally." 

Follow News & Updates from Shield Therapeutics here: